Does Rallies show 13F holders for TECH?

Yes. Rallies tracks hedge fund and 13F ownership data for TECH, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TECH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TECH. It does not provide personalized investment advice.

TECH (Bio-Techne Corp.) Stock Analysis - Hedge Fund Holdings

Bio-Techne Corp. (TECH) is a publicly traded Healthcare sector company. As of May 21, 2026, TECH trades at $46.69 with a market cap of $6.96B and a P/E ratio of 64.94. TECH moved +2.74% today. Year to date, TECH is -25.91%; over the trailing twelve months it is -5.71%. Its 52-week range spans $43.20 to $80.80. Analyst consensus is buy with an average price target of $59.25. Rallies surfaces TECH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TECH stock?

Hedge funds tracked by Rallies that own TECH include Maverick Capital, Glenview Capital, Polen Capital, Mangrove Partners, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bio-Techne Corp..

TECH Key Metrics

Key financial metrics for TECH
Metric	Value
Price	$46.69
Market Cap	$6.96B
P/E Ratio	64.94
EPS	$0.71
Dividend Yield	0.08%
52-Week High	$80.80
52-Week Low	$43.20
Volume	2.26M
Avg Volume	0
Revenue (TTM)	$1.21B
Net Income	$109.56M
Gross Margin	64.96%

Top Hedge Funds Holding TECH

Maverick Capital holds 4.74M shares of TECH, changed +23.08% as of Mar 31, 2026.
Glenview Capital holds 186.31K shares of TECH, changed -69.95% as of Mar 31, 2026.
Polen Capital holds 46.31K shares of TECH, changed +123.09% as of Mar 31, 2025.
Mangrove Partners holds 10.24K shares of TECH, changed +0.00% as of Mar 31, 2026.
Panagora Asset holds 6.80K shares of TECH, changed +0.00% as of Mar 31, 2026.

Latest TECH News

Bio-Techne sinks as fiscal Q3 revenue misses on weaker academic demand — May 6, 2026
Bio-Techne Q3 Revenue Dips to $311.4M, EPS Mixed, Declares $0.08 Dividend — May 6, 2026
Bio-Techne climbs as investors position ahead of May 6 fiscal Q3 earnings — May 5, 2026
Bio-Techne jumps ahead of May 6 earnings as analysts refocus on outlook — Apr 30, 2026
Bio-Techne slides as traders de-risk ahead of May 6 earnings report — Apr 29, 2026

Recent TECH Insider Trades

Herr Amy E. sold 1.98K (~$116.79K) on Feb 17, 2026.
Nusse Roeland sold 17.04K (~$960.39K) on Aug 25, 2025.
BAUMGARTNER ROBERT V sold 17.04K (~$957.82K) on Aug 25, 2025.

TECH Analyst Consensus

10 analysts cover TECH: 0 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $59.25.

Common questions about TECH

Who owns TECH stock?: Hedge funds tracked by Rallies that own TECH include Maverick Capital, Glenview Capital, Polen Capital, Mangrove Partners, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Bio-Techne Corp..
Does Rallies show 13F holders for TECH?: Yes. Rallies tracks hedge fund and 13F ownership data for TECH, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TECH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TECH. It does not provide personalized investment advice.